- EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
- EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
- EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
- EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
- EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
- EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
- EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
- EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
- EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
More ▼
Key statistics
On Wednesday, Edap Tms SA (EDAP:NMQ) closed at 6.84, 90.00% above the 52 week low of 3.60 set on Nov 14, 2023.
52-week range
Open | 7.08 |
---|---|
High | 7.08 |
Low | 6.81 |
Bid | 5.35 |
Offer | 8.50 |
Previous close | 6.84 |
Average volume | 29.82k |
---|---|
Shares outstanding | 37.10m |
Free float | 12.42m |
P/E (TTM) | -- |
Market cap | 253.79m USD |
EPS (TTM) | -0.6125 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼